RESULTS IN ELDERLY CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS TREATED WITH 5-AZACYTIDINE.
(Abstract release date: 05/19/16)
EHA Library. De Miguel Llorente D. 06/09/16; 134922; PB2022
Dunia De Miguel Llorente
Contributions
Contributions
Abstract
Abstract: PB2022
Type: Publication Only
Background
Two hypomethylating (HMT) agents,5-azacytidine (AZA)and decitabine have been approved by the FDA for the treatment of CMML. Initial data on HMT efficacy came from studies in patients with high-risk myelodysplastic syndrome (MDS), including, however, only a few cases of CMML. Hypomethylating agents are associated with overall response rates of approximately 30% to 40%, with complete remission rates of about 15%.
Aims
Evaluate efficacy and security of AZA in CMML patients.
Methods
we retrospectively collected clinical data of 8 patients (7 males/1 females) with a median age of 80 years (range72-86) diagnosed with CMML and treated with AZA, in our institution between 2010-2015.
Results
5 (63%) patients were diagnosed as CMML-1 and 3 (37%) patients as having CMML-2 subtype. AZA was administered at 75mg/m2 daily for 7 days, every four weeks. Response was assessed after median number of 6 cycles. Our patient cohort received a median number of 17 cycles (3-30) of therapy. Overall survival was 42 months (25-74 months). Progression free survival was 23 months (4-28 months). The median time to first response was 4 months. Causes of death were: 3 patients (38%) did evolution to AML (median time to progression 3 months). 3 patients had a sepsis. 1 patient had a lung cancer.
Conclusion
AZA in elderly CMML patients is efficacy and safety. The response were quickly and cytopenias were controlled.
Session topic: E-poster
Keyword(s): Elderly, Hypomethylation
Type: Publication Only
Background
Two hypomethylating (HMT) agents,5-azacytidine (AZA)and decitabine have been approved by the FDA for the treatment of CMML. Initial data on HMT efficacy came from studies in patients with high-risk myelodysplastic syndrome (MDS), including, however, only a few cases of CMML. Hypomethylating agents are associated with overall response rates of approximately 30% to 40%, with complete remission rates of about 15%.
Aims
Evaluate efficacy and security of AZA in CMML patients.
Methods
we retrospectively collected clinical data of 8 patients (7 males/1 females) with a median age of 80 years (range72-86) diagnosed with CMML and treated with AZA, in our institution between 2010-2015.
Results
5 (63%) patients were diagnosed as CMML-1 and 3 (37%) patients as having CMML-2 subtype. AZA was administered at 75mg/m2 daily for 7 days, every four weeks. Response was assessed after median number of 6 cycles. Our patient cohort received a median number of 17 cycles (3-30) of therapy. Overall survival was 42 months (25-74 months). Progression free survival was 23 months (4-28 months). The median time to first response was 4 months. Causes of death were: 3 patients (38%) did evolution to AML (median time to progression 3 months). 3 patients had a sepsis. 1 patient had a lung cancer.
Conclusion
AZA in elderly CMML patients is efficacy and safety. The response were quickly and cytopenias were controlled.
Session topic: E-poster
Keyword(s): Elderly, Hypomethylation
Abstract: PB2022
Type: Publication Only
Background
Two hypomethylating (HMT) agents,5-azacytidine (AZA)and decitabine have been approved by the FDA for the treatment of CMML. Initial data on HMT efficacy came from studies in patients with high-risk myelodysplastic syndrome (MDS), including, however, only a few cases of CMML. Hypomethylating agents are associated with overall response rates of approximately 30% to 40%, with complete remission rates of about 15%.
Aims
Evaluate efficacy and security of AZA in CMML patients.
Methods
we retrospectively collected clinical data of 8 patients (7 males/1 females) with a median age of 80 years (range72-86) diagnosed with CMML and treated with AZA, in our institution between 2010-2015.
Results
5 (63%) patients were diagnosed as CMML-1 and 3 (37%) patients as having CMML-2 subtype. AZA was administered at 75mg/m2 daily for 7 days, every four weeks. Response was assessed after median number of 6 cycles. Our patient cohort received a median number of 17 cycles (3-30) of therapy. Overall survival was 42 months (25-74 months). Progression free survival was 23 months (4-28 months). The median time to first response was 4 months. Causes of death were: 3 patients (38%) did evolution to AML (median time to progression 3 months). 3 patients had a sepsis. 1 patient had a lung cancer.
Conclusion
AZA in elderly CMML patients is efficacy and safety. The response were quickly and cytopenias were controlled.
Session topic: E-poster
Keyword(s): Elderly, Hypomethylation
Type: Publication Only
Background
Two hypomethylating (HMT) agents,5-azacytidine (AZA)and decitabine have been approved by the FDA for the treatment of CMML. Initial data on HMT efficacy came from studies in patients with high-risk myelodysplastic syndrome (MDS), including, however, only a few cases of CMML. Hypomethylating agents are associated with overall response rates of approximately 30% to 40%, with complete remission rates of about 15%.
Aims
Evaluate efficacy and security of AZA in CMML patients.
Methods
we retrospectively collected clinical data of 8 patients (7 males/1 females) with a median age of 80 years (range72-86) diagnosed with CMML and treated with AZA, in our institution between 2010-2015.
Results
5 (63%) patients were diagnosed as CMML-1 and 3 (37%) patients as having CMML-2 subtype. AZA was administered at 75mg/m2 daily for 7 days, every four weeks. Response was assessed after median number of 6 cycles. Our patient cohort received a median number of 17 cycles (3-30) of therapy. Overall survival was 42 months (25-74 months). Progression free survival was 23 months (4-28 months). The median time to first response was 4 months. Causes of death were: 3 patients (38%) did evolution to AML (median time to progression 3 months). 3 patients had a sepsis. 1 patient had a lung cancer.
Conclusion
AZA in elderly CMML patients is efficacy and safety. The response were quickly and cytopenias were controlled.
Session topic: E-poster
Keyword(s): Elderly, Hypomethylation
{{ help_message }}
{{filter}}